Cargando…
Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics
In molecular cancer therapeutics only 10% of known cancer gene products are targetable with current pharmacological agents. Major oncogenic drivers, such as MYC and KRAS proteins are frequently highly overexpressed or mutated in multiple human malignancies. However, despite their key role in oncogen...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002299/ https://www.ncbi.nlm.nih.gov/pubmed/31636382 http://dx.doi.org/10.1038/s41388-019-1056-3 |